Monday, November 9, 2020
- 9:00AM-11:00AM
-
Abstract Number: 1837
Clinical Outcomes in Lupus Nephritis by Renal Response Status: A Retrospective Analysis of the Hopkins Lupus Cohort
SLE – Treatment Poster II- 9:00AM-11:00AM
-
Abstract Number: 1640
Clinically Important Improvement in Osteoarthritis Pain at Week 16 After Subcutaneous Administration of Tanezumab: Pooled Analysis from International Studies
Osteoarthritis – Clinical Poster II- 9:00AM-11:00AM
-
Abstract Number: 1641
Clinically Important Improvements in Patients with Osteoarthritis Treated with Subcutaneous Tanezumab: Results from a 56-Week Randomized NSAID-Controlled Study
Osteoarthritis – Clinical Poster II- 9:00AM-11:00AM
-
Abstract Number: 1534
Combined Thermal and Ultrasound Imaging in Rheumatoid Arthritis Is Superior to Either Imaging Alone in Terms of Correlation with the 28-joint Disease Activity Score
Imaging of Rheumatic Diseases Poster- 9:00AM-11:00AM
-
Abstract Number: 1756
Comparable Long-Term Outcomes Among DAS28-ESR-based Remission Criteria and ACR/EULAR Definitions in Patients with Established Rheumatoid Arthritis
RA – Diagnosis, Manifestations, & Outcomes Poster IV: Lifespan of a Disease- 9:00AM-11:00AM
-
Abstract Number: 1898
Comparative Effectiveness of Secukinumab, Adalimumab and Other Tumor Necrosis Factor Inhibitors in the Treatment of Axial Spondyloarthritis
Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III: Axial SpA- 9:00AM-11:00AM
-
Abstract Number: 1730
Comparison of MBDA Score, Patient Global Assessment and Evaluator Global Assessment for Predicting Risk of Radiographic Progression
RA – Diagnosis, Manifestations, & Outcomes Poster IV: Lifespan of a Disease- 9:00AM-11:00AM
-
Abstract Number: 1648
Comparison of Methotrexate and Glucosamine in Primary Knee Osteoarthritis with Inflammation
Osteoarthritis – Clinical Poster II- 9:00AM-11:00AM
-
Abstract Number: 1637
Comparison of Nation-wide Epidemical Study on 2009 and That on 2019 Revealed That Improvement of Disease Severity and Mortality Rate May Come from Progress of Proficient Management in Patients with Relapsing Polychondritis in Japan
Miscellaneous Rheumatic & Inflammatory Diseases Poster III: Therapies- 9:00AM-11:00AM
-
Abstract Number: 1868
Comparison of Quality of Life Between Chronic Back Pain Patients with and Without a Diagnosis of Axial Spondyloarthritis After 2-Year Protocolised Follow-up: Data from the Spondyloarthritis Caught Early Cohort
Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III: Axial SpA- 9:00AM-11:00AM
-
Abstract Number: 1871
Comparison of Work Productivity Outcomes Between Chronic Back Pain Patients with and Without a Diagnosis of Axial Spondyloarthritis After 2-Year Protocolised Follow-Up: Data from the Spondyloarthritis Caught Early Cohort
Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III: Axial SpA- 9:00AM-11:00AM
-
Abstract Number: 1810
Complement Activation in Systemic Lupus Erythematosus Patients with Low Disease Activity Is Not Inhibited by Hydroxychloroquine
SLE – Diagnosis, Manifestations, & Outcomes Poster III: Bench to Bedside- 9:00AM-11:00AM
-
Abstract Number: 1828
Comprehensive Efficacy of Anifrolumab Across Organ Domains in Patients with Active SLE: Pooled Data from 2 Phase 3 Trials
SLE – Treatment Poster II